Form: CORRESP

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

December 18, 2020

[htbx_correspatm002.gif]

Heat Biologics, Inc.

627 Davis Drive, Suite 400

Morrisville, North Carolina 27560


December 18, 2020


VIA EDGAR


U.S. Securities and Exchange Commission

Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:  Alan Campbell

                  

 

 

 

 

Re:

Heat Biologics, Inc.

 

 

Registration Statement on Form S-3

 

 

File No. 333-251255


Dear Mr. Campbell:


Heat Biologics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-251255) be accelerated by the U.S. Securities and Exchange Commission to Tuesday, December 22, 2020 at 5:00 pm, New York City Time, or as soon as reasonably practicable thereafter.


The Company hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

 

 

 

 

 

 

 

Very truly yours,

 

 

 

Heat Biologics, Inc.

 

 

 

By:

 

/s/ Jeffrey Wolf

 

 

Name:  Jeffrey Wolf

 

 

Title:  Chief Executive Officer



cc: Leslie Marlow, Esq. (Gracin & Marlow, LLP)

      Patrick Egan, Esq. (Gracin & Marlow, LLP)